갑상선암 치료제 시장 : 암 유형, 치료법, 약제 유형, 투여 방법, 환자 연령층, 브랜드 상황, 최종 사용자별 - 세계 예측(2026-2032년)

The Thyroid Cancer Drugs Market is projected to grow by USD 2.14 billion at a CAGR of 11.15% by 2032.

The thyroid cancer drugs market is being reshaped by rising diagnosis, longer survivorship, and rapid adoption of biomarker-directed therapies. IARC GLOBOCAN 2022 reported more than 820,000 new thyroid cancer cases worldwide and about 47,500 deaths, underscoring a large treated population despite generally favorable outcomes in early-stage disease.

Commercial demand is concentrated across differentiated thyroid cancer, radioiodine-refractory disease, medullary thyroid cancer, and anaplastic thyroid cancer. Growth is increasingly tied to targeted drugs such as multikinase inhibitors, RET inhibitors, NTRK inhibitors, BRAF/MEK combinations, and supportive endocrine therapy that improves disease control and quality of life.

Transformative Shifts in the Thyroid Cancer Treatment Landscape

The competitive landscape is shifting from broadly used systemic therapy toward precision oncology. Established agents such as lenvatinib, sorafenib, cabozantinib, and vandetanib remain important, while selective RET inhibitors, tumor-agnostic NTRK inhibitors, and BRAF/MEK therapy have raised expectations for response, tolerability, and molecular testing.

Clinical practice is also changing through earlier genomic profiling, multidisciplinary tumor boards, and more active management of adverse events linked to chronic oral therapies. Payers and providers are placing greater weight on real-world evidence, duration of response, and patient-reported outcomes as treatment pathways become more personalized.

Cumulative Impact of Artificial Intelligence on Thyroid Cancer Drugs

Artificial intelligence is adding cumulative value across the thyroid cancer drugs value chain rather than acting as a standalone solution. AI-enabled ultrasound interpretation, digital pathology, radiomics, and natural language processing can help identify suspicious nodules, extract clinical data, and flag patients who may benefit from molecular testing or clinical trial referral.

For manufacturers and health systems, AI supports trial feasibility, pharmacovigilance, adherence monitoring, and real-world evidence generation. The highest-impact use cases require validated datasets, transparent models, privacy safeguards, and alignment with regulatory expectations for clinical decision support.

Key Regional Insights Across Global Thyroid Cancer Drug Demand

North America remains a high-value region because of broad access to molecular diagnostics, specialty oncology networks, clinical trial participation, and faster uptake of FDA-approved targeted therapies. Europe benefits from ESMO-aligned clinical practice, centralized health technology assessment, and growing emphasis on value-based reimbursement, although access timing varies by country and payer pathway.

Asia-Pacific is a major volume opportunity, led by China, India, Japan, South Korea, and Australia, with demand supported by diagnosis rates, hospital capacity expansion, population-based screening in several settings, and local oncology investment. Latin America shows improving specialist care in Brazil and Mexico but continues to face public-sector access gaps, while the Middle East is supported by national cancer strategies and tertiary care investment. Africa remains shaped by uneven diagnostic infrastructure, oncology workforce availability, pathology capacity, and reimbursement constraints.

Key Group Insights for Thyroid Cancer Drug Commercialization

Within ASEAN, thyroid cancer drug adoption is expanding as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines improve oncology access, though molecular testing availability and reimbursement remain uneven. GCC markets benefit from government-funded specialty hospitals, national cancer programs, and rising adoption of advanced therapeutics in Saudi Arabia, the UAE, Qatar, and neighboring countries.

The European Union is defined by HTA scrutiny, biospecimen standards, pharmacovigilance requirements, and harmonized regulatory pathways, while BRICS countries offer large patient pools, rising oncology infrastructure, and increasing relevance of local manufacturing and domestic clinical research. G7 markets lead in innovation, clinical trial density, biomarker testing, and premium therapy uptake, and NATO-aligned countries provide resilient pharmaceutical supply chains across many advanced economies while supporting cross-border regulatory and procurement coordination.

Key Country Insights Shaping Thyroid Cancer Drug Adoption

The United States leads in innovation, guideline-driven biomarker testing, specialist referral pathways, and access to FDA-approved targeted drugs, while Canada emphasizes evidence-based reimbursement and provincial formulary decisions. Mexico and Brazil are important Latin American markets where private-sector uptake is generally faster than public access. In Europe, the United Kingdom, Germany, France, Italy, and Spain show strong specialist care, established cancer centers, and structured reimbursement review, while Russia remains more sensitive to local access, procurement dynamics, and domestic supply considerations.

China and India offer major scale, rising cancer infrastructure, expanding genomic testing capacity, and growing domestic oncology capabilities. Japan combines advanced diagnostics, high treatment standards, and mature reimbursement processes, while South Korea supports rapid adoption through strong hospital systems and molecular oncology expertise. Australia supports broad evidence-based oncology care through structured reimbursement, specialist networks, and established clinical guideline use.

Actionable Recommendations for Thyroid Cancer Drug Industry Leaders

Industry leaders should prioritize broad molecular testing for RET, NTRK, BRAF, RAS, and other actionable alterations in appropriate patients, supported by companion diagnostics, pathologist engagement, and clinician education. Portfolio strategies should balance established multikinase inhibitors with precision therapies that address smaller but high-value biomarker-defined populations.

Commercial success depends on market access evidence, adverse-event management programs, patient adherence support, and region-specific affordability models. Companies should also invest in real-world registries, AI governance, decentralized trial capabilities, and partnerships with cancer centers to improve recruitment, evidence generation, and continuity of care.

Research Methodology for Evidence-Based Market Insights

This executive summary is based on triangulation of publicly available, authoritative sources, including WHO/IARC GLOBOCAN cancer statistics, FDA and EMA drug approval information, NCCN and ESMO treatment guidance, clinical trial registries, peer-reviewed oncology literature, and health technology assessment patterns.

The methodology emphasizes verified disease burden indicators, approved treatment classes, regional healthcare infrastructure, reimbursement dynamics, diagnostic availability, and observable adoption trends. Insights were synthesized to support strategic planning while avoiding unsupported market-size claims, market-share assumptions, or speculative forecasts.

Conclusion: Precision Medicine Defines the Next Growth Phase

The thyroid cancer drugs market is moving toward precision-led, evidence-driven care. While many patients with localized thyroid cancer have favorable outcomes, advanced, metastatic, radioiodine-refractory, medullary, and anaplastic disease continue to create strong demand for innovative systemic therapies.

Future market leadership will be shaped by biomarker testing, differentiated clinical evidence, equitable access, and disciplined use of AI-enabled tools. Organizations that combine scientific depth with regional access strategies are better positioned to support sustainable growth and improved patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Thyroid Cancer Drugs Market, by Cancer Type

• 7.1. Anaplastic Thyroid Cancer (ATC)
• 7.2. Follicular Thyroid Cancer (FTC)
• 7.3. Hurthle Cell Carcinoma
• 7.4. Medullary Thyroid Cancer (MTC)
• 7.5. Papillary Thyroid Cancer (PTC)

8. Thyroid Cancer Drugs Market, by Treatment Modality

• 8.1. Chemotherapy
• 8.2. Immunotherapy
• 8.3. Radioiodine Therapy
• 8.4. Surgery
• 8.5. Targeted Multikinase Therapy
• 8.6. Thyroid Stimulating Hormone (TSH) Suppression Therapy

9. Thyroid Cancer Drugs Market, by Drug Type

• 9.1. Chemotherapy Agents
• 9.2. Hormone Therapy Drugs
• 9.3. Immunotherapy Drugs
• 9.4. Targeted Therapy Drugs

10. Thyroid Cancer Drugs Market, by Mode Of Administration

• 10.1. Injectable
  • 10.1.1. Pre-Filled Syringes
  • 10.1.2. Vials
• 10.2. Oral
  • 10.2.1. Capsules
  • 10.2.2. Tablets

11. Thyroid Cancer Drugs Market, by Patient Age Group

• 11.1. Pediatric
• 11.2. Adult
• 11.3. Geriatric

12. Thyroid Cancer Drugs Market, by Brand Status

• 12.1. Branded
• 12.2. Generic

13. Thyroid Cancer Drugs Market, by End User

• 13.1. Homecare Settings
• 13.2. Hospitals
• 13.3. Oncology Clinics
• 13.4. Research Organizations

14. Thyroid Cancer Drugs Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Thyroid Cancer Drugs Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Thyroid Cancer Drugs Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Abbott Ltd.
• 18.2. AbbVie Inc.
• 18.3. Amgen Inc.
• 18.4. Aprazer Healthcare Pvt Ltd.
• 18.5. AstraZeneca PLC
• 18.6. Bayer AG
• 18.7. Biovista Inc.
• 18.8. Blueprint Medicines Corporation
• 18.9. Bristol-Myers Squibb Company
• 18.10. Cellectar Biosciences, Inc.
• 18.11. Dr Reddy's Laboratories Ltd.
• 18.12. Eisai Co., Ltd.
• 18.13. Eli Lilly and Company
• 18.14. Exelixis, Inc.
• 18.15. Genentech, Inc
• 18.16. GlaxoSmithKline PLC
• 18.17. Glenmark Pharmaceuticals Ltd.
• 18.18. Hetero Healthcare Limited
• 18.19. Ipsen SA
• 18.20. Janssen Pharmaceuticals, Inc.
• 18.21. Lupin Limited
• 18.22. Merck & Co., Inc.
• 18.23. MSN Laboratories
• 18.24. Natco Pharma Ltd.
• 18.25. Novartis AG
• 18.26. Pfizer Inc.
• 18.27. Roche Holding AG
• 18.28. Sanofi S.A.
• 18.29. Takeda Pharmaceutical Company Limited
• 18.30. Teva Pharmaceutical Industries Ltd
• 18.31. Vascular Biogenics Ltd.
• 18.32. Viatris Inc.